Differences in real-world pembrolizumab dosing patterns
In this poster, Divya Natesan from the University of Pittsburgh sought to examine the frequency of using a 3-weekly versus a 6-weekly dosing of pembrolizumab in a real-world context. Additionally, she explored whether there were any disparities between academic hospitals and peripheral hospitals.
With the educational support of:
